IDXX Stock Overview
Develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
IDXX passed our risk checks.
IDEXX Laboratories, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$418.61 |
| 52 Week High | US$583.39 |
| 52 Week Low | US$404.74 |
| Beta | 1.36 |
| 11 Month Change | -7.67% |
| 3 Month Change | -14.87% |
| 1 Year Change | -12.49% |
| 33 Year Change | -32.75% |
| 5 Year Change | 66.98% |
| Change since IPO | 44,182.73% |
Recent News & Updates
At US$420, Is It Time To Put IDEXX Laboratories, Inc. (NASDAQ:IDXX) On Your Watch List?
Nov 19
IDEXX Laboratories Q3: Weak End-Market Demand Continues
Nov 11Investors Appear Satisfied With IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Prospects
Oct 28Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 15Recent updates
At US$420, Is It Time To Put IDEXX Laboratories, Inc. (NASDAQ:IDXX) On Your Watch List?
Nov 19IDEXX Laboratories Q3: Weak End-Market Demand Continues
Nov 11Investors Appear Satisfied With IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Prospects
Oct 28Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 15We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Sep 18A Look At The Intrinsic Value Of IDEXX Laboratories, Inc. (NASDAQ:IDXX)
Sep 05What Is IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Doing?
Aug 20IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits
Aug 12A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital
Jul 02Looking For Fast Growth In Healthcare? IDEXX Has You Covered
Jun 28Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jun 04Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?
May 21IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 03What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You
Apr 27IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)
Apr 08Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jan 30IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified
Jan 16Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jan 15IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit
Dec 31IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Oct 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 10Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jul 04These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?
Apr 05Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Jan 05Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Nov 24When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Sep 20IDEXX Laboratories: Outstanding Business, But Valuation Is Key
Aug 15These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
Aug 15IDEXX Laboratories Stock Is Very Expensive
Aug 08IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M
Aug 02Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?
Jul 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today
Jul 12Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jun 16IDEXX Laboratories: Great Business, But Still Overvalued
May 25Shareholder Returns
| IDXX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.6% | -0.4% | -1.0% |
| 1Y | -12.5% | 20.3% | 30.3% |
Return vs Industry: IDXX underperformed the US Medical Equipment industry which returned 20.3% over the past year.
Return vs Market: IDXX underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| IDXX volatility | |
|---|---|
| IDXX Average Weekly Movement | 3.9% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IDXX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IDXX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 11,000 | Jay Mazelsky | www.idexx.com |
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community.
IDEXX Laboratories, Inc. Fundamentals Summary
| IDXX fundamental statistics | |
|---|---|
| Market cap | US$34.09b |
| Earnings (TTM) | US$866.24m |
| Revenue (TTM) | US$3.84b |
39.6x
P/E Ratio8.9x
P/S RatioIs IDXX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDXX income statement (TTM) | |
|---|---|
| Revenue | US$3.84b |
| Cost of Revenue | US$1.51b |
| Gross Profit | US$2.33b |
| Other Expenses | US$1.47b |
| Earnings | US$866.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.58 |
| Gross Margin | 60.72% |
| Net Profit Margin | 22.53% |
| Debt/Equity Ratio | 54.0% |
How did IDXX perform over the long term?
See historical performance and comparison